SG11201802956RA - Colloidal particles for use in medicine - Google Patents
Colloidal particles for use in medicineInfo
- Publication number
- SG11201802956RA SG11201802956RA SG11201802956RA SG11201802956RA SG11201802956RA SG 11201802956R A SG11201802956R A SG 11201802956RA SG 11201802956R A SG11201802956R A SG 11201802956RA SG 11201802956R A SG11201802956R A SG 11201802956RA SG 11201802956R A SG11201802956R A SG 11201802956RA
- Authority
- SG
- Singapore
- Prior art keywords
- medicine
- colloidal particles
- colloidal
- particles
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1518172.0A GB201518172D0 (en) | 2015-10-14 | 2015-10-14 | Colloidal particles for use in medicine |
| PCT/EP2016/074759 WO2017064276A1 (en) | 2015-10-14 | 2016-10-14 | Colloidal particles for use in medicine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201802956RA true SG11201802956RA (en) | 2018-05-30 |
Family
ID=55131025
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202010711UA SG10202010711UA (en) | 2015-10-14 | 2016-10-14 | Colloidal Particles for Use in Medicine |
| SG11201802956RA SG11201802956RA (en) | 2015-10-14 | 2016-10-14 | Colloidal particles for use in medicine |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202010711UA SG10202010711UA (en) | 2015-10-14 | 2016-10-14 | Colloidal Particles for Use in Medicine |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20190192664A1 (en) |
| EP (1) | EP3362039A1 (en) |
| JP (1) | JP7160678B2 (en) |
| KR (1) | KR20180067616A (en) |
| CN (1) | CN108472246A (en) |
| AU (1) | AU2016336929B2 (en) |
| BR (1) | BR112018007399A2 (en) |
| CA (1) | CA3036111C (en) |
| EA (1) | EA201890703A1 (en) |
| GB (1) | GB201518172D0 (en) |
| HK (1) | HK1256814A1 (en) |
| IL (1) | IL258567A (en) |
| MX (1) | MX2018004445A (en) |
| SG (2) | SG10202010711UA (en) |
| WO (1) | WO2017064276A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202111759D0 (en) * | 2021-08-17 | 2021-09-29 | Cantab Biopharmaceuticals Patents Ltd | Modified colloidal particles |
| GB202111757D0 (en) * | 2021-08-17 | 2021-09-29 | Cantab Biopharmaceuticals Patents Ltd | Modified colloidal particles for use in the treatment of haemophilia A |
| GB202111758D0 (en) * | 2021-08-17 | 2021-09-29 | Cantab Biopharmaceuticals Patents Ltd | Modified colloidal particles for use in the treatment of haemophilia A |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| ES2131206T3 (en) | 1993-08-06 | 1999-07-16 | Opperbas Holding Bv | A METHOD OF HIGH LOADING OF VESICLES WITH BIOPOLYMER SUBSTANCES. |
| AU747391B2 (en) | 1998-04-27 | 2002-05-16 | Cantab Biopharmaceuticals Patents Limited | Pharmaceutical composition comprising factor VIII and neutral liposomes |
| US6294192B1 (en) * | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
| AU769517B2 (en) | 1999-07-14 | 2004-01-29 | Alza Corporation | Neutral lipopolymer and liposomal compositions containing same |
| US20030232075A1 (en) * | 2002-05-06 | 2003-12-18 | University Of Minnesota, A Minnesota Corporation | Compositions for producing factor Xa |
| CN1774281B (en) * | 2003-04-15 | 2010-10-13 | 奥珀百思控股公司 | Pharmaceutical composition comprising proteins and/or polypeptides and colloidal particles |
| BRPI0612843A2 (en) * | 2005-06-29 | 2010-11-30 | Univ New York State Res Found | pharmaceutical composition, methods for manufacturing the composition, and use of a formulation |
| GB2483419B (en) | 2009-06-03 | 2015-04-08 | Sequessome Technology Holdings Ltd | Formulations for the treatment of deep tissue pain |
| MX336482B (en) | 2009-08-21 | 2016-01-21 | Henk-Andre Kroon | Vesicular formulations. |
| GB201007357D0 (en) | 2010-04-30 | 2010-06-16 | Leverton Licence Holdings Ltd | Conjugated factor VIII |
| GB201007356D0 (en) | 2010-04-30 | 2010-06-16 | Leverton Licence Holdings Ltd | Conjugated factor VIIa |
| JP2015512927A (en) | 2012-04-16 | 2015-04-30 | カンタブ バイオファーマシューティカルズ パテンツ リミテッド | Optimized subcutaneous therapy |
| CA2904184C (en) * | 2013-03-08 | 2021-09-07 | Novartis Ag | Lipids and lipid compositions for the delivery of active agents |
-
2015
- 2015-10-14 GB GBGB1518172.0A patent/GB201518172D0/en not_active Ceased
-
2016
- 2016-10-14 SG SG10202010711UA patent/SG10202010711UA/en unknown
- 2016-10-14 KR KR1020187013254A patent/KR20180067616A/en not_active Application Discontinuation
- 2016-10-14 WO PCT/EP2016/074759 patent/WO2017064276A1/en active Application Filing
- 2016-10-14 CN CN201680073237.XA patent/CN108472246A/en active Pending
- 2016-10-14 CA CA3036111A patent/CA3036111C/en active Active
- 2016-10-14 JP JP2018519423A patent/JP7160678B2/en active Active
- 2016-10-14 SG SG11201802956RA patent/SG11201802956RA/en unknown
- 2016-10-14 BR BR112018007399A patent/BR112018007399A2/en not_active Application Discontinuation
- 2016-10-14 AU AU2016336929A patent/AU2016336929B2/en active Active
- 2016-10-14 US US15/768,381 patent/US20190192664A1/en not_active Abandoned
- 2016-10-14 EA EA201890703A patent/EA201890703A1/en unknown
- 2016-10-14 EP EP16781807.9A patent/EP3362039A1/en active Pending
- 2016-10-14 MX MX2018004445A patent/MX2018004445A/en unknown
-
2018
- 2018-04-09 IL IL258567A patent/IL258567A/en unknown
- 2018-12-11 HK HK18115899.0A patent/HK1256814A1/en unknown
-
2020
- 2020-05-26 US US16/883,338 patent/US20210093721A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20180067616A (en) | 2018-06-20 |
| MX2018004445A (en) | 2018-08-14 |
| WO2017064276A1 (en) | 2017-04-20 |
| GB201518172D0 (en) | 2015-11-25 |
| BR112018007399A2 (en) | 2018-10-16 |
| EA201890703A1 (en) | 2018-11-30 |
| CN108472246A (en) | 2018-08-31 |
| CA3036111A1 (en) | 2017-04-20 |
| EP3362039A1 (en) | 2018-08-22 |
| IL258567A (en) | 2018-05-31 |
| CA3036111C (en) | 2023-06-06 |
| US20210093721A1 (en) | 2021-04-01 |
| JP2018535952A (en) | 2018-12-06 |
| HK1256814A1 (en) | 2019-10-04 |
| JP7160678B2 (en) | 2022-10-25 |
| AU2016336929B2 (en) | 2022-09-29 |
| AU2016336929A1 (en) | 2018-05-10 |
| SG10202010711UA (en) | 2020-12-30 |
| US20190192664A1 (en) | 2019-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1244000B (en) | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use | |
| GB2524085B (en) | Exception handling in microprocessor systems | |
| IL251630A0 (en) | Combination therapy for use in cancer therapy | |
| PL3046983T3 (en) | Multilayer grinding particle | |
| SG11201700968PA (en) | Formulation comprising particles | |
| IL251905A0 (en) | Apilimod for use in the treatment of renal cancer | |
| ZA201502203B (en) | Nano particulate delivery system | |
| IL251371A0 (en) | Cortexolone 17alpha-benzoate for use in the treatment of tumours | |
| IL250507B (en) | Anti-ck8 antibodies for use in the treatment of cancers | |
| IL248424B (en) | Neuro-protective agents and uses thereof | |
| GB201521304D0 (en) | Tokenisation in cardholder - not - present transactions | |
| EP3177304A4 (en) | Therapeutic nanoparticles for accumulation in the brain | |
| HK1256814A1 (en) | Colloidal particles for use in medicine | |
| GB201701400D0 (en) | Compound for use in medicine | |
| SG11201606034WA (en) | Device for delivering particles | |
| GB201616880D0 (en) | Compound for use in medicine | |
| GB201516107D0 (en) | Complexes and methods for their preparation | |
| GB201701388D0 (en) | Compound for use in medicine | |
| GB201416493D0 (en) | Polypeptides for use in therapy | |
| GB201404831D0 (en) | Animalistic studies in nature | |
| GB201409978D0 (en) | Novel compounds and their use in therapy |